Your AI-Trained Oncology Knowledge Connection!
The clinical trial of tebentafusp (IMCgp100) versus investigator’s choice in metastatic uveal melanoma met its pre-defined boundaries for statistical significance of the primary end point of overall survival in its first pre-planned interim analysis.
Study investigators indicated that these results call for the need to revise skin cancer health policies to be able to handle the increasing burden of keratinocyte carcinoma management.
Adil Daud, MD, spoke about the emergence of next-generation sequencing and the importance of testing patients with melanoma for BRAF mutations.
Jeffrey Weber, MD, PhD, discusses the unmet needs professionals take into consideration when deciding treatment options for patients with melanoma.
Data from the COMBI-AD Trial evaluating dabrafenib and trametinib to treat melanoma was analyzed by Hussein Tawbi, MD, PhD, of The University of Texas MD Anderson Cancer Center.
CancerNetwork spoke with Jason Luke, MD, FACP, at the SMR Conference regarding the latest updates on melanoma.
“The data reported, in addition to its ease of use, demonstrate the potential of [tavokinogene telseplasmid] in combination with pembrolizumab as a next-generation intratumoral IL-12 therapy that can induce regression of both locally treated and untreated distant and visceral lesions,” said Paolo A. Ascierto, MD.
Results from this study suggest that this combination is active and should be considered for this patient population, though additional research is still necessary.
Pretreatment circulating tumor DNA was found to be a reliable indicator of patient outcome for those with metastatic melanoma in the first-line immune checkpoint inhibitor (ICI) treatment setting, but not in the second-line setting.
A study published in JAMA Dermatology determined that topical immunosuppressant medications used to treat adult patients with atopic dermatitis do not increase the risk of common forms of cancer despite warning labels on the packaging.
The study is evaluating the nivolumab-ipilimumab combination versus nivolumab alone in patients who have had a complete surgical removal of stage IIIb/c/d or stave IV melanoma.
Data for the phase 3 COMBI-i trial showed that spartalizumab combined with dabrafenib and trametinib did not meet its primary end xpoint of investigator-assessed progression-free survival.
Cemiplimab demonstrated an objective response rate of 31% in patients with locally advanced basal cell carcinoma who progress on or are intolerant to hedgehog inhibitors.
Partner Therapeutics, Inc. announced that its EA6141 study evaluating sargramostim in combination with ipilumimab and nivolumab to treat melanoma was approved to begin enrollment.
The study was evaluating spartalizumab in combination with dabrafenib and trametinib among untreated patients with stage IIIC or stage IV BRAFV600 mutation-positive cutaneous melanoma.
Data released from a phase 2b clinical trial showed statistically significant long-term survival for patients with stage III or IV melanoma at high-risk of recurrence.
The FDA approved atezolizumab plus cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive advanced melanoma.
The FDA approved pembrolizumab for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.
Clinically important increases in melanoma risk in patients treated with biologic therapy for common inflammatory diseases cannot yet be ruled out based on current evidence.
The combination of tavo and pembrolizumab was associated with a higher than anticipated response rate in patients with advanced melanoma with low frequencies of checkpoint positive cytotoxic lymphocytes.
Researchers indicated that targeted approaches to improving time from diagnosis to definitive surgery for black patients are essential in reducing racial disparities in melanoma outcomes.
Cemiplimab showed clinically meaningful and durable responses in this group of patients for whom there are no currently approved treatments.
Interim data from cohort B of KEYNOTE-555, a phase I trial evaluating a 400 mg every 6-week dosing regimen of pembrolizumab in patients with metastatic melanoma, demonstrated a consistent benefit-risk profile.
Favorable toxicity profiles and antitumor activity seen in this phase II study of pembrolizumab supports further evaluation of the drug in this patient population.
A study showed that adolescents and young adults with certain types of cancers saw significant improvements in their 5-year mortality rates, while other cancer types saw little to no significant improvement among the same demographic group.
